The Law Offices of Nicholas Koluncich III, LLC is investigating possible breaches of fiduciary duty by certain officers and directors of Orexigen Theraputics, Inc. (Nasdaq: OREX) (“Orexigen” or “Company”). Although Orexigen’s public filings made to the Securities and Exchange Commission inform that the Company’s business operations focus on the development of pharmaceutical products for the treatment of obesity, its recent public filings also disclose developments which could have substantial bearing on your rights as an Orexigen shareholder. To have your voice as a shareholder heard in a possible lawsuit concerning these confidential matters or to discretely discuss this matter with an attorney at no cost to you, you are encouraged to swiftly contact us at the contact information below. We encourage current shareholders, former employees and any other persons having knowledge about the company to confidentially contact us.
If you own Orexigen shares or have any questions concerning your rights or interests with respect to the Company, please contact The Law Offices of Nicholas Koluncich III, LLC. The initial attorney consultation is free of charge and all information shall be treated as attorney client privileged and confidential. Although the outcome of litigation is never assured, as an Orexigen shareholder, you may be eligible for some form of financial recovery.
The Law Offices of Nicholas Koluncich III, LLC6501 Americas Parkway NEOne Park Square – Suite 820Albuquerque, NM 87110505-881-2228fax 505-881-4288 email@example.com
The Law Offices of Nicholas Koluncich III, LLC has been representing individual and institutional investors for over a decade, serving as counsel in numerous securities and derivative litigations in U.S. Federal and state courts.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts